158 related articles for article (PubMed ID: 21382019)
1. Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.
Foroni L; Wilson G; Gerrard G; Mason J; Grimwade D; White HE; de Castro DG; Austin S; Awan A; Burt E; Clench T; Farruggia J; Hancock J; Irvine AE; Kizilors A; Langabeer S; Milner BJ; Nickless G; Schuh A; Sproul A; Wang L; Wickham C; Cross NC
Br J Haematol; 2011 Apr; 153(2):179-90. PubMed ID: 21382019
[TBL] [Abstract][Full Text] [Related]
2. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
[TBL] [Abstract][Full Text] [Related]
3. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
[TBL] [Abstract][Full Text] [Related]
4. Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK.
Cross NCP; White HE; Evans PAS; Hancock J; Copland M; Milojkovic D; Mason J; Craine S; Mead AJ
Br J Haematol; 2018 Sep; 182(6):777-788. PubMed ID: 30125955
[TBL] [Abstract][Full Text] [Related]
5. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.
Boeckx N; Laer CV; Roover JD; Wilmsen B; Bruyninckx K; Pauwels S
Acta Clin Belg; 2015 Aug; 70(4):237-43. PubMed ID: 26166681
[TBL] [Abstract][Full Text] [Related]
6. [Guidelines for molecular monitoring of BCR-ABL1 in chronic myeloid leukemia patients by RT-qPCR].
Larripa I; Ruiz MS; Gutiérrez M; Bianchini M
Medicina (B Aires); 2017; 77(1):61-72. PubMed ID: 28140313
[TBL] [Abstract][Full Text] [Related]
7. Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients.
Koren-Michowitz M; Shimoni A; Daraio F; Crasto F; Lorenzatti R; Volchek Y; Amariglio N; Gottardi E; Saglio G; Nagler A
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1852-5. PubMed ID: 26151304
[TBL] [Abstract][Full Text] [Related]
8. Molecular monitoring in CML and the prospects for treatment-free remissions.
Deininger MW
Hematology Am Soc Hematol Educ Program; 2015; 2015():257-63. PubMed ID: 26637731
[TBL] [Abstract][Full Text] [Related]
9. Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization.
Cross NC; Hochhaus A; Müller MC
Ann Hematol; 2015 Apr; 94 Suppl 2():S219-25. PubMed ID: 25814088
[TBL] [Abstract][Full Text] [Related]
10. BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia.
Press RD; Kamel-Reid S; Ang D
J Mol Diagn; 2013 Sep; 15(5):565-76. PubMed ID: 23810242
[TBL] [Abstract][Full Text] [Related]
11. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.
Bartley PA; Ross DM; Latham S; Martin-Harris MH; Budgen B; Wilczek V; Branford S; Hughes TP; Morley AA
Int J Lab Hematol; 2010 Dec; 32(6 Pt 1):e222-8. PubMed ID: 20491997
[TBL] [Abstract][Full Text] [Related]
12. Measurement of BCR-ABL1 by RT-qPCR in chronic myeloid leukaemia: findings from an International EQA Programme.
Scott S; Travis D; Whitby L; Bainbridge J; Cross NCP; Barnett D
Br J Haematol; 2017 May; 177(3):414-422. PubMed ID: 28295199
[TBL] [Abstract][Full Text] [Related]
13. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
14. Molecular monitoring in CML: how deep? How often? How should it influence therapy?
Shanmuganathan N; Hughes TP
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):168-176. PubMed ID: 30504306
[TBL] [Abstract][Full Text] [Related]
15. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
[TBL] [Abstract][Full Text] [Related]
16. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients.
McCarron SL; O'Connor LM; Langabeer SE; Conneally E
Genet Test Mol Biomarkers; 2013 Feb; 17(2):170-3. PubMed ID: 23289634
[TBL] [Abstract][Full Text] [Related]
18. Implication of the Autologous Immune System in BCR-ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib.
Clapp GD; Lepoutre T; El Cheikh R; Bernard S; Ruby J; Labussière-Wallet H; Nicolini FE; Levy D
Cancer Res; 2015 Oct; 75(19):4053-62. PubMed ID: 26359456
[TBL] [Abstract][Full Text] [Related]
19. Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia.
Moore FR; Rempfer CB; Press RD
Methods Mol Biol; 2013; 999():1-23. PubMed ID: 23666687
[TBL] [Abstract][Full Text] [Related]
20. Molecular monitoring of chronic myeloid leukemia: international standardization of BCR-ABL1 quantitation.
Zhen C; Wang YL
J Mol Diagn; 2013 Sep; 15(5):556-64. PubMed ID: 23876601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
